Nelma Clementino

571 total citations
17 papers, 352 citations indexed

About

Nelma Clementino is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, Nelma Clementino has authored 17 papers receiving a total of 352 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Hematology, 6 papers in Genetics and 6 papers in Rheumatology. Recurrent topics in Nelma Clementino's work include Chronic Myeloid Leukemia Treatments (11 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Eosinophilic Disorders and Syndromes (5 papers). Nelma Clementino is often cited by papers focused on Chronic Myeloid Leukemia Treatments (11 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Eosinophilic Disorders and Syndromes (5 papers). Nelma Clementino collaborates with scholars based in Brazil, Spain and Canada. Nelma Clementino's co-authors include Milena Soriano Marcolino, Antônio Luiz Pinho Ribeiro, Gifone Aguiar Rocha, Dulciene Maria Magalhães Queiroz, Andréia Maria Camargos Rocha, Fabrício Freire de Melo, Márcia M. Barbosa, Maria Carmo Pereira Nunes, Carolina C. Souza and Adriana Bozzi and has published in prestigious journals such as Blood, Gut and Annals of Oncology.

In The Last Decade

Nelma Clementino

16 papers receiving 334 citations

Peers

Countries citing papers authored by Nelma Clementino

Since Specialization

Citations

This map shows the geographic impact of Nelma Clementino's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nelma Clementino with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nelma Clementino more than expected).

Fields of papers citing papers by Nelma Clementino

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nelma Clementino. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nelma Clementino. The network helps show where Nelma Clementino may publish in the future.

Co-authorship network of co-authors of Nelma Clementino

This figure shows the co-authorship network connecting the top 25 collaborators of Nelma Clementino. A scholar is included among the top collaborators of Nelma Clementino based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nelma Clementino. Nelma Clementino is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	PF411 ENESTOP 192‐WK RESULTS: DURABILITY AND IMPACT ON QUALITY OF LIFE OF TREATMENT‐FREE REMISSION (TFR) FOLLOWING SECOND‐LINE (2L) NILOTINIB (NIL) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA (CML) 2019 ·HemaSphere ·François‐Xavier Mahon, Carla Boquimpani, (unknown), Noam Benyamini, Nelma Clementino, Vasily Shuvaev, J. H. Lipton, Anna Turkina, Raquel De Paz Arias, Beatriz Moiraghi, Franck E. Nicolini, Jolanta Dengler, Tomasz Sacha, (unknown), (unknown), (unknown), (unknown), Timothy P. Hughes	1
2	Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results 2017 ·Leukemia ·Timothy P. Hughes, Brian Leber, Francisco Cervantes, Nelson Spector, Ricardo Pasqüini, Nelma Clementino, Anthony P. Schwarer, P.E. Dorlhiac‐Llacer, F-X Mahon, Delphine Réa, A. Guerci-Bresler, Suzanne Kamel‐Reid, Israel Bendit, (unknown), (unknown), Darshan Dalal, Susan Branford, J. H. Lipton	31
3	Cytokine profile of patients with chronic immune thrombocytopenia affects platelet count recovery after Helicobacter pylori eradication 2014 ·British Journal of Haematology ·Andréia Maria Camargos Rocha, (unknown), Fabrício Freire de Melo, Nelma Clementino, (unknown), Gifone Aguiar Rocha, Dulciene Maria Magalhães Queiroz	17
4	Achievement and Maintenance Of Deeper Molecular Response By Switching To Nilotinib In Patients (pts) With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) With Residual Disease On Long-Term Imatinib: ENESTcmr 36-Month Follow-Up 2013 ·Blood ·Brian Leber, Francisco Cervantes, Nelson Spector, Jeffrey H. Lipton, Gabriel Étienne, Ricardo Pasqüini, Nelma Clementino, Agnès Guerci‐Bresler, Donna L. Forrest, Anthony P. Schwarer, (unknown), (unknown), Tomasz Szczudlo, Timothy P. Hughes	5
5	Switching to Nilotinib Is Associated with Continued Deeper Molecular Responses in CML-CP Patients with Minimal Residual Disease After ≥ 2 Years On Imatinib: Enestcmr 2-Year Follow-up Results 2012 ·Blood ·Timothy P. Hughes, Jeffrey H. Lipton, Nelson Spector, Brian Leber, Ricardo Pasqüini, Nelma Clementino, Anthony P. Schwarer, Gabriel Étienne, Agnès Guerci‐Bresler, Susan Branford, Das Purkayastha, (unknown), Tomasz Szczudlo, Francisco Cervantes	4
6	The levels of IL-17A and of the cytokines involved in Th17 cell commitment are increased in patients with chronic immune thrombocytopenia 2011 ·Haematologica ·Andréia Maria Camargos Rocha, Carolina C. Souza, Gifone Aguiar Rocha, Fabrício Freire de Melo, Nelma Clementino, (unknown), Adriana Bozzi, (unknown), (unknown), Dulciene Maria Magalhães Queiroz	93
7	Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients 2011 ·Annals of Oncology ·Milena Soriano Marcolino, Eric Boersma, Nelma Clementino, Antônio Vaz de Macedo, (unknown), (unknown), Teun van Gelder, K. Martijn Akkerhuis, Antônio Luiz Pinho Ribeiro	56
8	Complete Molecular Response (CMR) Rate with Nilotinib in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) without CMR After ≥ 2 Years on Imatinib: Preliminary Results From the Randomized ENESTcmr Trial of Nilotinib 400 Mg Twice Daily (BID) Vs Imatinib 2011 ·Blood ·Timothy P. Hughes, Jeffrey H. Lipton, Brian Leber, Nelson Spector, Francisco Cervantes, Ricardo Pasqüini, Nelma Clementino, Anthony P. Schwarer, François‐Xavier Mahon, Delphine Réa, David T Yeung, Suzanne Kamel‐Reid, Israel Bendit, John Reynolds, Lisa Williams, Tomasz Szczudlo, Susan Branford	7
9	The use of imatinib mesylate has no adverse effects on the heart function. Results of a pilot study in patients with chronic myeloid leukemia 2010 ·Leukemia Research ·Milena Soriano Marcolino, Antônio Luiz Pinho Ribeiro, Nelma Clementino, Maria Carmo Pereira Nunes, Márcia M. Barbosa, (unknown), (unknown), Marcel L. Geleijnse, Eric Boersma	10
10	The duration of the use of imatinib mesylate is only weakly related to elevated BNP levels in chronic myeloid leukaemia patients 2010 ·Hematological Oncology ·Milena Soriano Marcolino, Eric Boersma, Nelma Clementino, Maria Carmo Pereira Nunes, Márcia M. Barbosa, (unknown), Marcel L. Geleijnse, Antônio Luiz Pinho Ribeiro	13
11	Transplante alogênico de células-tronco hematopoéticas em leucemias agudas: a experiência de dez anos do Hospital das Clínicas da UFMG 2010 ·Revista Brasileira de Hematologia e Hemoterapia ·(unknown), Nelma Clementino, (unknown), (unknown), Henrique Bittencourt	7
12	Mieloma múltiplo: características clínicas e laboratoriais ao diagnóstico e estudo prognóstico 2009 ·Revista Brasileira de Hematologia e Hemoterapia ·(unknown), (unknown), (unknown), Rosa Malena Delbone de Faria, Nelma Clementino, (unknown), (unknown)	10
13	Imatinib mesylate versus allogeneic BMT for patients with chronic myeloid leukemia in first chronic phase 2008 ·Bone Marrow Transplantation ·Henrique Bittencourt, Vaneuza Araújo Moreira Funke, Laura Fogliatto, (unknown), D.C. Setubal, (unknown), Antônio Vaz de Macedo, (unknown), (unknown), Lúcia Mariano da Rocha Silla, Nelma Clementino, Ricardo Pasqüini	20
14	An evaluation of the cardiotoxicity of imatinib mesylate 2008 ·Leukemia Research ·Antônio Luiz Pinho Ribeiro, Milena Soriano Marcolino, (unknown), Márcia M. Barbosa, Maria Carmo Pereira Nunes, (unknown), Nelma Clementino	55
15	Mieloma múltiplo: verificação do conhecimento da doença em médicos que atuam na atenção primária à saúde 2008 ·Revista Brasileira de Hematologia e Hemoterapia ·(unknown), Rosa Malena Delbone de Faria, (unknown), Nelma Clementino, (unknown), (unknown), (unknown)	0
16	Long-term effect of Helicobacter pylori eradication on plasma homocysteine in elderly patients with cobalamin deficiency 2006 ·Gut ·(unknown), Cláudio Alvarenga de Oliveira, Andréia Maria Camargos Rocha, Gifone Aguiar Rocha, Nelma Clementino, Luís Antunes, Rodrigo Azevedo de Oliveira, Almir S. Martins, Helen L. Del Puerto, Vânia D’Almeida, Luciano Galdieri, Ênio Roberto Pietra Pedroso, Mônica Maria Demas Álvares Cabral, Ana Margarida Miguel Ferreira Nogueira, Dulciene Maria Magalhães Queiroz	21
17	Observacional Study for Evaluation of Quality of Life in Patients with Chronic Myeloid Leukemia (CML) in Use of Gleevec® (Imatinib Mesilate). 2004 ·Blood ·Ricardo Pasqüini, Nelma Clementino, Maria Aparecida Zanichelli, (unknown), (unknown), Carlos Chiattone, (unknown), (unknown), (unknown), (unknown), Lúcia Mariano da Rocha Silla, (unknown), (unknown), Cármino Antônio De Souza, (unknown), (unknown), Eduardo Magalhães Rego, Cláudia Cristina Ferreira Vasconcelos	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact